Elizabeth Schwoch, LCSW | |
Usag Hohenfels, Cmr 414 Box 2353, Apo, AE 09173 | |
(480) 525-0284 | |
Not Available |
Full Name | Elizabeth Schwoch |
---|---|
Gender | Female |
Speciality | Social Worker - Clinical |
Location | Usag Hohenfels, Apo, Armed Forces Europe |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083810014 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YA0400X | Counselor - Addiction (substance Use Disorder) | 11749 (Arizona) | Secondary |
1041C0700X | Social Worker - Clinical | 12964 (Arizona) | Primary |
Mailing Address | Practice Location Address |
---|---|
Elizabeth Schwoch, LCSW Cmr 414, Box 2353, Apo, AE 09173 Ph: () - | Elizabeth Schwoch, LCSW Usag Hohenfels, Cmr 414 Box 2353, Apo, AE 09173 Ph: (480) 525-0284 |
News Archive
A selection of health policy stories from California, Maine, Massachusetts, Maryland, New Hampshire, Virginia, Iowa, Florida, Missouri, Washington state, Connecticut, Georgia, Alabama, North Carolina and Tennessee.
Physical and cognitive rest are traditionally what doctors prescribe for patients who suffer sport-related concussions. But a new approach to treating post-concussion syndrome may actually help athletes get back in the game quicker, according to Karl Kozlowski, PhD, assistant professor of kinesiology at Canisius College in Buffalo, NY.
In May 2009, Riverview Medical Center became part of a research study sponsored by Johns Hopkins University called the Atlantic C-PORT-E Elective Angioplasty trial. Riverview was selected to participate in this research study for its high level of experience and outstanding cardiovascular services.
Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today financial results for the second quarter ended April 30, 2011.
Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
› Verified 8 days ago